Human Herpesviruses 6A, 6B, and 7.

Area of Science:

• Virology
• Immunology
• Infectious Diseases

Background:

• Human roseoloviruses, including HHV-6A, HHV-6B, and HHV-7, are genetically related to human cytomegalovirus and establish lifelong latent infections.
• While many infections are asymptomatic, these viruses can cause severe opportunistic diseases, particularly in immunocompromised patients like transplant recipients and those with AIDS.
• A subset of the population (1%) harbors chromosomally integrated HHV-6 (ciHHV-6).

Purpose of the Study:

• To review the clinical impact and diagnostic challenges of human herpesviruses 6A, 6B, and 7 (HHV-6A, HHV-6B, HHV-7).
• To discuss the current therapeutic options and highlight pending questions regarding HHV infections in immunocompromised patients.

Main Methods:

• Review of current literature on HHV-6A, HHV-6B, and HHV-7.
• Discussion of diagnostic techniques, including limitations of serology and antigen detection.
• Emphasis on real-time PCR for viral DNA quantification in various body fluids and tissues.

Main Results:

• HHV-6 and HHV-7 infections can manifest as asymptomatic primary infections, reactivations, or reinfections.
• Severe manifestations include central nervous system, bone marrow, lung, gastrointestinal, skin, and liver involvement, notably encephalitis in HSCT recipients.
• Antiviral agents like ganciclovir, foscarnet, and cidofovir show efficacy, but treatment guidelines are not standardized.

Conclusions:

• Accurate diagnosis of HHV infections, especially in immunocompromised hosts, relies heavily on sensitive molecular methods like real-time PCR.
• The clinical significance and optimal management of HHV-6A, HHV-6B, and HHV-7 infections, particularly in immunocompromised individuals, require further investigation and consensus.
• Addressing the pending questions regarding clinical impact and therapeutic strategies is crucial for improving patient outcomes.